548 related articles for article (PubMed ID: 31002604)
1. Tumor Hypoxia: A Key Determinant of Microenvironment Hostility and a Major Checkpoint during the Antitumor Response.
Francis A; Venkatesh GH; Zaarour RF; Zeinelabdin NA; Nawafleh HH; Prasad P; Buart S; Terry S; Chouaib S
Crit Rev Immunol; 2018; 38(6):505-524. PubMed ID: 31002604
[TBL] [Abstract][Full Text] [Related]
2. The Antitumor Cytotoxic Response: If the Killer Cells Play the Music, the Microenvironmental Hypoxia Plays the Tune.
Chouaib S
Crit Rev Immunol; 2020; 40(2):157-166. PubMed ID: 32749093
[TBL] [Abstract][Full Text] [Related]
3. Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy.
Abou Khouzam R; Goutham HV; Zaarour RF; Chamseddine AN; Francis A; Buart S; Terry S; Chouaib S
Semin Cancer Biol; 2020 Oct; 65():140-154. PubMed ID: 31927131
[TBL] [Abstract][Full Text] [Related]
4. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer.
Chouaib S; Noman MZ; Kosmatopoulos K; Curran MA
Oncogene; 2017 Jan; 36(4):439-445. PubMed ID: 27345407
[TBL] [Abstract][Full Text] [Related]
5. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy.
Pitt JM; Marabelle A; Eggermont A; Soria JC; Kroemer G; Zitvogel L
Ann Oncol; 2016 Aug; 27(8):1482-92. PubMed ID: 27069014
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-/HIF-1α-Driven Factors of the Tumor Microenvironment Impeding Antitumor Immune Responses and Promoting Malignant Progression.
Vaupel P; Multhoff G
Adv Exp Med Biol; 2018; 1072():171-175. PubMed ID: 30178341
[TBL] [Abstract][Full Text] [Related]
7. Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets.
Ray SK; Mukherjee S
Curr Drug Targets; 2022; 23(5):471-485. PubMed ID: 35021970
[TBL] [Abstract][Full Text] [Related]
8. Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges.
Noman MZ; Hasmim M; Lequeux A; Xiao M; Duhem C; Chouaib S; Berchem G; Janji B
Cells; 2019 Sep; 8(9):. PubMed ID: 31540045
[TBL] [Abstract][Full Text] [Related]
9. Advanced nanotechnology for hypoxia-associated antitumor therapy.
Zhao L; Fu C; Tan L; Li T; Zhong H; Meng X
Nanoscale; 2020 Feb; 12(5):2855-2874. PubMed ID: 31965135
[TBL] [Abstract][Full Text] [Related]
10. Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity.
Terry S; Faouzi Zaarour R; Hassan Venkatesh G; Francis A; El-Sayed W; Buart S; Bravo P; Thiery J; Chouaib S
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301213
[TBL] [Abstract][Full Text] [Related]
11. Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity.
Janji B; Berchem G; Chouaib S
Front Immunol; 2018; 9():887. PubMed ID: 29922284
[TBL] [Abstract][Full Text] [Related]
12. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
13. Targeting hypoxic tumor microenvironment in pancreatic cancer.
Tao J; Yang G; Zhou W; Qiu J; Chen G; Luo W; Zhao F; You L; Zheng L; Zhang T; Zhao Y
J Hematol Oncol; 2021 Jan; 14(1):14. PubMed ID: 33436044
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Checkpoints: Novel Avenues for Immunotherapy of Cancer.
Shevchenko I; Bazhin AV
Front Immunol; 2018; 9():1816. PubMed ID: 30131808
[TBL] [Abstract][Full Text] [Related]
15. Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies.
Abou Khouzam R; Brodaczewska K; Filipiak A; Zeinelabdin NA; Buart S; Szczylik C; Kieda C; Chouaib S
Front Immunol; 2020; 11():613114. PubMed ID: 33552076
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes?
Abou Khouzam R; Zaarour RF; Brodaczewska K; Azakir B; Venkatesh GH; Thiery J; Terry S; Chouaib S
Front Immunol; 2022; 13():828875. PubMed ID: 35211123
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia.
Noman MZ; Hasmim M; Messai Y; Terry S; Kieda C; Janji B; Chouaib S
Am J Physiol Cell Physiol; 2015 Nov; 309(9):C569-79. PubMed ID: 26310815
[TBL] [Abstract][Full Text] [Related]
18. Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy.
Wang B; Zhao Q; Zhang Y; Liu Z; Zheng Z; Liu S; Meng L; Xin Y; Jiang X
J Exp Clin Cancer Res; 2021 Jan; 40(1):24. PubMed ID: 33422072
[TBL] [Abstract][Full Text] [Related]
19. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
Rohwer N; Cramer T
Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
